The research, led by Francesco Berinato and colleagues at the University of Brescia and ASST Spedali Civili Hospital in Italy, focused on two proteins that have become central to the emerging field of blood-based neurology: neurofilament light chain, abbreviated NfL, and glial fibrillary acidic protein, known as GFAP. NfL is a structural component of the long, cable-like projections of neurons, and when axons are injured, fragments of this protein leak into the surrounding fluid and eventually reach the bloodstream. GFAP, by contrast, is a scaffolding protein found in astrocytes, the star-shaped support cells of the brain, and it rises when these glial cells are damaged or activated. Because each protein reports on a different cellular population, measuring both together provides a two-channel view of brain injury, capturing damage to neurons and to their supporting architecture simultaneously.

The technical challenge has always been sensitivity. Concentrations of NfL and GFAP in blood are vanishingly small, measured in picograms per milliliter, or trillionths of a gram. Conventional immunoassays simply could not detect these levels reliably in plasma. The Brescia team turned to single molecule array technology, or Simoa, an ultrasensitive digital detection platform that counts individual protein molecules by trapping them in microscopic wells studded with magnetic beads and reading out fluorescent signals one bead at a time. This approach, which has transformed research into neurodegenerative disease, made it possible to quantify subtle elevations in proteins released by microscopic, transient brain injury that no scanner can see.

The study design was deliberately conservative. The researchers enrolled 36 patients who had experienced a clinically defined TIA but whose brain MRI showed no infarct, meaning no visible stroke lesion. Each patient was matched by age and sex to two healthy controls, yielding a comparison group of 72 individuals. Blood samples were drawn within 24 hours of hospital admission, a window chosen to capture proteins while injury-related release was still at or near its peak. The team then performed group comparisons, constructed receiver operating characteristic curves to identify optimal diagnostic thresholds, and ran a series of sensitivity analyses designed to strip out confounding factors that could artificially inflate biomarker levels.

The results were striking. Patients with MRI-negative TIA had plasma NfL concentrations averaging 27.22 picograms per milliliter, more than two and a half times the control average of 10.44 picograms per milliliter, a difference that was highly statistically significant. GFAP told a similar story, averaging 301.99 picograms per milliliter in patients versus 131.65 in controls. In other words, even when the brain looked perfectly normal on imaging, the blood carried a chemical record of injury. The findings held up when the researchers systematically excluded patients with pre-existing disability, previous stroke or TIA, impaired kidney function, a heavy burden of small vessel disease on MRI, and moderate to severe cortical atrophy, all conditions known to raise NfL or GFAP independently of any acute event.

The diagnostic performance of each marker revealed an interesting asymmetry. The optimal cutoff for NfL was 16.83 picograms per milliliter, a threshold that achieved remarkable specificity of 98.6 percent, meaning that almost no healthy individual exceeded it, but sensitivity of only 52.8 percent, meaning it flagged only about half of the TIA patients. GFAP at a cutoff of 179.23 picograms per milliliter was more balanced, with sensitivity of 69.4 percent and specificity of 81.9 percent. The most powerful result emerged when the two proteins were interpreted together. A combined assessment raised sensitivity to 80.6 percent while preserving specificity at 81.9 percent, and produced the highest discriminative accuracy of any configuration tested, with an area under the curve of 0.812. The complementary biology makes sense of this: axonal injury and astroglial activation are partially independent processes, so a patient whose injury is too subtle to push one marker over threshold may still push the other.

Why does this matter clinically? TIA is fundamentally a warning sign, a brief interruption of blood flow that predicts a substantial risk of subsequent full stroke, particularly in the days and weeks that follow. Current guidelines rely on clinical scoring systems, imaging to exclude stroke mimics, and urgent vascular workup to stratify risk. But a substantial fraction of suspected TIAs remain diagnostically ambiguous, especially when imaging is negative and symptoms have fully resolved. Objective blood markers could help confirm that a transient neurological event genuinely reflected brain ischemia rather than a mimic such as migraine aura, seizure, or peripheral vestibular disorder. They could also, in principle, help quantify the tissue impact of the event, complementing what imaging cannot show.

The broader context is a field in rapid motion. Prior work has established that NfL rises acutely after overt ischemic stroke, correlates with stroke severity, and predicts functional outcome, and a recent individual patient data meta-analysis consolidated the diagnostic and prognostic value of blood NfL in ischemic stroke. GFAP has shown promise in distinguishing stroke types and mapping the timeline of tissue impact after acute cerebrovascular events. What the Brescia study adds is a crucial piece of that puzzle: evidence that the biomarker signal is not merely a byproduct of large, scan-visible infarcts, but reflects genuine microscopic injury even in the mildest end of the ischemic spectrum. This aligns with a growing recognition that TIA is not a benign non-event but a real injury whose consequences, including subtle cognitive decline after first-time TIA, may be underestimated by conventional imaging.

Important caveats remain, and the authors are careful to acknowledge them. The study was single-center and retrospective, with a modest sample of 36 patients, and the control group, while carefully matched, cannot capture the full diversity of patients who present to emergency departments with TIA-like symptoms. Specificity figures derived from healthy controls will likely look different against real-world differential diagnoses, where conditions such as renal impairment, trauma, and neurodegenerative disease can elevate the same proteins. The sensitivity analyses go a long way toward addressing these concerns, but the authors themselves state that larger studies are needed to confirm clinical utility before such tests enter routine practice.

Even so, the trajectory is clear. Blood-based biomarkers are moving from the research bench toward the stroke unit, propelled by ultrasensitive platforms like Simoa and by accumulating evidence across the cerebrovascular disease spectrum. A simple blood draw taken within a day of a suspected TIA, interpreted alongside clinical scores and imaging, could one day transform one of neurology’s most uncertain diagnoses into a measurable, quantifiable event. For patients who are told their scan is clean but their symptoms were real, the blood may soon provide the answer that the scanner cannot, confirming that even the briefest storm in the brain leaves its mark, written in the language of proteins, detectable in a few milliliters of plasma.

Subject of Research: Blood biomarkers NfL and GFAP for detecting microscopic brain injury in MRI-negative transient ischemic attack

Article Title: Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP

Article References: Berinato, F., Morotti, A., Baronchelli, G., Tolassi, C., Girotto, I., Pilotto, A., & Padovani, A. (2026). Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP. Journal of Neurology, 273(10), Article 580. https://doi.org/10.1007/s00415-026-14097-1

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14097-1

Keywords: transient ischemic attack, TIA, neurofilament light chain, GFAP, blood biomarkers, brain injury, stroke, Simoa, MRI, neurology, cerebrovascular disease, plasma biomarkers

The study, led by Irene Scala of the Cerebrovascular Unit at Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan and conducted on behalf of the Italian Stroke Association (ISA)-Young, set out to answer a deceptively simple question: what actually happens when patients receive repeated intravenous thrombolysis (RIVT) for a recurrent acute ischemic stroke within 90 days of a previous thrombolysis-treated event? The researchers systematically screened the literature and identified 28 reports describing 63 patients who underwent the procedure, with individual patient-level data available for 44 of those cases. That patient-level granularity matters enormously in a field dominated by small case series, because it allowed the team to analyze outcomes at the level of individual strokes rather than pooled study averages, reducing the aggregation bias that has plagued earlier reviews.

The headline finding is striking. Among patients who received a second course of intravenous thrombolysis within the three-month window, 66.7 percent achieved a favorable functional outcome — a proportion that compares respectably with outcomes reported for first-time thrombolysis in routine clinical registries. The median interval between the two treatments was just 7.5 days, meaning most of these patients were re-dosed while their initial infarcts were still biologically fresh, precisely the scenario in which the feared hemorrhagic risk was thought to be highest. Yet across the entire dataset, not a single case of symptomatic intracranial hemorrhage (sICH) — the dreaded complication that the three-month exclusion criterion was designed to prevent — was recorded after repeated thrombolysis.

Formal meta-analysis reinforced the picture. The pooled odds ratio for better functional outcomes after repeated thrombolysis was 1.52, with a 95 percent confidence interval of 0.97 to 2.39 and zero heterogeneity across studies (I² = 0%). The confidence interval crosses one, so the trend toward benefit does not reach statistical significance, but the direction is consistent and the absence of heterogeneity suggests the underlying case reports tell a remarkably uniform story. Equally important, the analysis found no significant increase in functional deterioration between stroke episodes, with a pooled odds ratio of 1.28 (95% CI 0.75–2.19; I² = 0%). In other words, patients did not systematically worsen after their second stroke, and there was no signal that the repeat treatment itself drove neurological decline.

Perhaps the most clinically useful aspect of the analysis is what it ruled out. The researchers tested whether outcomes were influenced by the interval between treatments, patient age, sex, stroke etiology, vascular territory, or the time from symptom onset to treatment — and found that none of these factors significantly shaped results. This null finding directly undermines the logic of a fixed temporal cutoff. If the safety of a second dose does not measurably depend on how many days have elapsed since the first stroke, then a rigid three-month clock may be the wrong instrument for judging risk. Instead, the data suggest clinicians should weigh the individual biology of each recurrence rather than the calendar.

The safety signal was not entirely clean, and the authors are careful to report it. Asymptomatic intracranial or systemic hemorrhages occurred in 15.9 percent of patients — bleeding visible on imaging or detected clinically but not causing neurological worsening. Fatal events occurred in 5 percent of cases, but crucially, these deaths were unrelated to neurological complications. Both hemorrhagic and fatal events clustered predominantly in patients with cardioembolic strokes and more severe initial presentations, hinting that the underlying mechanism of recurrence and stroke severity, rather than the repeat thrombolysis itself, may drive adverse outcomes. This pattern aligns with mechanistic reasoning: cardioembolic strokes, often arising from atrial fibrillation or cardiac thrombi, tend to be larger and more lethal, and patients with severe deficits have more tissue at risk regardless of treatment.

To understand why the three-month rule exists at all, one has to look back to the founding trials of stroke thrombolysis. The 1995 NINDS trial of tissue plasminogen activator, which established alteplase as standard care, excluded patients with recent stroke, and subsequent guidelines from the European Stroke Organisation and the American Heart Association/American Stroke Association carried the exclusion forward as a relative contraindication grounded largely in expert consensus rather than dedicated trials of repeat dosing. The biological rationale — that freshly infarcted brain and reperfused vessels are more prone to bleeding — has never been disproven, but it has also never been rigorously quantified in the recurrent-stroke setting. Meanwhile, the clinical dilemma is real and growing: patients with active sources of embolism, unstable atherosclerotic plaques, carotid webs, free-floating thrombi, or basilar artery occlusions can suffer devastating recurrent strokes days or weeks after a first event, and withholding thrombolysis from them may condemn them to disability or death.

The new analysis, registered prospectively in PROSPERO (CRD420251276423) and conducted according to PRISMA 2020 reporting standards, synthesizes a literature that spans two decades of case reports and small series — from early accounts of imaging-guided repeat dosing in 2005 to multicenter case studies of ultra-early re-treatment published in 2023. The authors used the Heidelberg bleeding classification to standardize hemorrhage assessment and performed the meta-analysis with established statistical tooling. By extracting individual patient data wherever possible, they converted a scattered, anecdotal literature into something approaching coherent evidence — a methodological upgrade that previous systematic reviews of the same question, which relied on aggregated study-level data, could not achieve.

The caveats are substantial and the authors acknowledge them plainly. Repeated thrombolysis within 90 days is a rare event, and its efficacy remains understudied; the 63 patients analyzed come from published reports that are inherently subject to publication bias, since dramatic successes and instructive failures are more likely to reach print than unremarkable outcomes. There are no randomized trials, no matched controls who were denied repeat thrombolysis, and no way to fully separate the effect of treatment from the effect of careful patient selection — the very clinicians who chose to re-treat these patients presumably judged them to be favorable candidates. The favorable outcomes observed may partly reflect that selection rather than the safety of the drug itself. Five percent mortality, even if neurologically unrelated, is not negligible in an already fragile population.

Still, the conclusion the authors draw is measured and potentially practice-changing: repeated intravenous thrombolysis within 90 days may be a reasonable reperfusion strategy in carefully selected patients with recurrent acute ischemic stroke, and the interval from the previous stroke should not be treated as an isolated exclusion criterion. In an era when mechanical thrombectomy is increasingly available but not always feasible — particularly for distal vessel occlusions or in centers without endovascular capability — the finding suggests that the pharmacological route should not be automatically closed by the calendar. The evidence is observational and thin, but for a rule that has governed stroke units worldwide on the strength of consensus alone, the burden of proof may now have shifted. Larger, prospective registries of recurrent stroke treatment will be needed to confirm whether the zero-sICH finding holds at scale, but for clinicians facing a deteriorating patient with a fresh recurrence, this analysis offers something they have rarely had: data suggesting that saying yes to a second dose may not be the reckless act the guidelines have long implied.

Subject of Research: Safety and efficacy of repeated intravenous thrombolysis within three months for recurrent acute ischemic stroke

Article Title: Safety and efficacy of repeated intravenous thrombolysis within 3 months for acute ischemic stroke: a systematic review and individual-patient data meta-analysis

Article References: Scala, I., Ciacciarelli, A., Cancelloni, V., Digiovanni, A., Galotto, D., Gardin, A., Giammello, F., & the Italian Stroke Association (ISA)-Young (2026). Safety and efficacy of repeated intravenous thrombolysis within 3 months for acute ischemic stroke: a systematic review and individual-patient data meta-analysis. Journal of Neurology, 273(10), Article 607. https://doi.org/10.1007/s00415-026-14144-x

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14144-x

Keywords: stroke, intravenous thrombolysis, recurrent stroke, alteplase, symptomatic intracranial hemorrhage, meta-analysis, systematic review, cerebrovascular disease, reperfusion therapy, stroke guidelines, neurology, thrombolytic drugs

The research team, led by Xiaoxiao Song of the Second Affiliated Hospital of Guangxi University of Chinese Medicine together with colleagues from the Nanning Hospital of Traditional Chinese Medicine and Guangxi Medical University, analyzed 2,382 hospital admissions for acute ischemic stroke recorded between July 1, 2017, and June 30, 2020. The records came from a single tertiary hospital in Nanning, a city whose humid subtropical climate makes it a useful natural laboratory for studying how heat and cold shape cerebrovascular risk. On an average day, the hospital admitted just over two stroke patients, a modest daily count that nevertheless accumulates into a dataset rich enough to detect subtle weather-related patterns.

Methodologically, the study leans on two statistical workhorses of environmental epidemiology. The first is the quasi-Poisson generalized linear model, which handles daily count data such as hospital admissions and accommodates the overdispersion—variance exceeding the mean—that is typical of such series. The second is the distributed lag nonlinear model, or DLNM, a framework that allows researchers to estimate simultaneously how an exposure like temperature affects risk in a nonlinear way and how that effect is spread across time. Rather than asking only whether a hot day produces more strokes on that same day, the DLNM can trace the risk across a window of lag days, here spanning zero to seven days after exposure, and can compute cumulative effects over any sub-window within that range.

The team anchored its comparisons to the median daily mean temperature of 23.30 degrees Celsius, treating this as the reference point against which hotter and colder days were judged. When the mean temperature rose to 29.60 degrees Celsius—a level well within Nanning’s summer routine—the risk of an ischemic stroke admission increased substantially. The relative risk reached 1.347, with a 95 percent confidence interval of 1.058 to 1.714, when cumulative effects over lag days zero to one were considered, and climbed to 1.396 (95 percent CI: 1.085 to 1.797) over lag days zero to two. In practical terms, on such hot days the hospital could expect roughly 35 to 40 percent more ischemic stroke admissions than on a typical day at the median temperature.

Just as striking as the size of the effect is its timing. The association between high temperature and stroke admissions attenuated as the lag window lengthened, fading over longer cumulative periods. This pattern suggests that heat acts as a near-immediate trigger rather than a slow-burning risk factor: the physiological damage it inflicts on vulnerable patients appears to translate into arterial blockages within hours to a couple of days. That short latency has real operational implications, because it means emergency services and stroke units can anticipate surges in demand almost in real time as heat waves roll through a city, rather than bracing for a delayed wave of cases.

The biological plausibility of a rapid heat effect is well supported by prior research. Heat stress promotes dehydration, which hemoconcentrates the blood and increases viscosity, tilting the hemostatic balance toward clot formation. Sweating-driven fluid loss also reduces plasma volume, and studies of heat-stressed humans have documented measurable changes in coagulation responses. Heat further strains the cardiovascular system by increasing cardiac output and cutaneous blood flow to shed excess warmth, while aging blood vessels lose some of their thermoregulatory reflex capacity. Endothelial function, the ability of blood vessel linings to dilate and maintain smooth flow, is itself temperature-sensitive. Inflammatory and coagulation markers rise in hot conditions, and blood pressure—normally lower in warm weather—can fluctuate in ways that destabilize existing atherosclerotic plaques. Any of these pathways could, in a patient with narrowed cerebral arteries, tip the balance toward an occlusive event within a single hot day.

Cold told a different and less conclusive story. When the mean temperature dropped to 10.50 degrees Celsius, the same-day risk estimate was lower than for heat, and the cumulative associations over longer lag windows were inconsistent. The authors are careful here: they note that the low-temperature findings require cautious interpretation. This asymmetry is not unusual in subtropical settings, where winters are mild and cold extremes are relatively rare, limiting the statistical power to detect cold effects. It also contrasts with studies from temperate and northern Chinese cities, such as Beijing and Guangzhou, where distributed lag analyses have often found robust cold-related increases in stroke admissions with longer lag times. The divergence underscores a central theme in climate-health research: temperature effects are regionally heterogeneous, shaped by local climate norms, housing, air conditioning prevalence, and the physiological adaptation of the population.

Recognizing how easily time-series findings can be artifacts of modeling choices, the researchers ran an extensive battery of sensitivity analyses. They varied how the long-term trend and seasonality were adjusted in the models, added air pollutant concentrations as covariates to rule out confounding by poor air quality, changed the maximum lag period, excluded the year 2020—a year distorted by the COVID-19 pandemic’s disruption of hospital care—and adjusted for the Spring Festival window, during which hospital utilization patterns in China shift dramatically. The main findings held up across these checks, lending confidence that the heat-stroke link is not a statistical mirage. The robustness of the hot-temperature effect, contrasted with the fragility of the cold-temperature signal, reinforces the study’s central conclusion.

The stakes of this line of research are rising with the thermometer. Ischemic stroke imposes an enormous global burden, and analyses of the Global Burden of Disease data show it remains a leading cause of death and long-term disability worldwide, with China bearing a particularly heavy share. The World Stroke Organization has issued a scientific statement on stroke and climate change, warning that warming temperatures will translate into additional cerebrovascular events. Meanwhile, studies using hourly heat exposure data have begun to show that even short bursts of high temperature can precipitate ischemic stroke, and occupational health research documents widespread heat stress in working populations. Against that backdrop, a study pinpointing a one-to-two-day window of elevated risk gives public health authorities something actionable: heat-health warning systems can be tuned not just to warn the general population but to alert hospitals, ambulance dispatch, and thrombolysis-capable stroke centers to prepare for demand spikes within 48 hours of extreme heat.

The study’s limitations are those inherent to its design. It draws on admissions from a single tertiary hospital in one city over three years, so the results may not generalize to regions with different climates or to populations with different demographics and healthcare access. Hospital admissions capture only patients who reach care, and prehospital delay—known to be common in stroke—could interact with weather in ways the data cannot reveal. The authors also emphasize that the cold-temperature association, being less consistent, should not be overinterpreted. Still, the core message is clear and increasingly hard to ignore: in a warming world, the days immediately following a heat spike are precisely when vulnerable brains are most at risk, and health systems that plan for that window may save not just comfort but lives.

Subject of Research: The short-term association between ambient mean temperature and hospital admissions for acute ischemic stroke in a subtropical Chinese city.

Article Title: Association between mean temperature and hospital admissions for acute ischemic stroke: a time-series study

Article References: Association between mean temperature and hospital admissions for acute ischemic stroke: a time-series study. (n.d.). https://doi.org/10.1007/s11869-026-02102-5

Image Credits: AI Generated

DOI: 10.1007/s11869-026-02102-5

Keywords: acute ischemic stroke, ambient temperature, heat, hospital admissions, distributed lag nonlinear model, time-series analysis, Nanning, China, climate change, cerebrovascular disease, public health, epidemiology

The analogy is more than rhetorical. Cardiovascular medicine underwent its own conceptual revolution after discovering that the sheer size of an atherosclerotic plaque poorly predicts who will have a heart attack. Many severely narrowed arteries remain silent for life, while acute events often arise from lesions causing only modest narrowing. What matters is not the presence of plaque but its biological behavior: inflammatory activity, lipid composition, the integrity of the fibrous cap, neovascularization, intraplaque hemorrhage, endothelial dysfunction, and thrombotic susceptibility. Cardiovascular risk is now understood as a dynamic interplay between the pathological substrate and systemic modifiers, including age, genetics, hypertension, diabetes, dyslipidemia, obesity, smoking, chronic inflammation, physical inactivity, diet, and environmental exposures. Plaque detection marks increased biological risk, not an inevitable cardiac event.

Alzheimer’s disease, the authors argue, has reached the same stage of conceptual maturity. Amyloid accumulation may initiate or facilitate downstream processes, but the transition from biological pathology to clinical dementia is shaped by their interaction with tau propagation, neuroinflammation, synaptic dysfunction, cerebrovascular injury, metabolic alterations, genetic susceptibility, co-existing pathologies, and mechanisms of resilience. Within this framework, amyloid remains indispensable to the biological definition of Alzheimer’s disease, but its clinical significance depends on the biological context in which it occurs. This multidimensional view helps explain why individuals with comparable amyloid burden can follow markedly different trajectories, and why amyloid positivity alone does not equate to clinical Alzheimer’s disease.

Some of the strongest evidence that amyloid and dementia can be uncoupled comes, paradoxically, from the population in which the amyloid cascade hypothesis is best supported: carriers of autosomal dominant Alzheimer’s mutations. In the Colombian PSEN1 E280A kindred, the largest such family in the world, affected members typically develop mild cognitive impairment around age 44 and dementia around age 49, with amyloid deposition detectable more than two decades before symptoms. Yet within this genetically homogeneous cohort, two carriers have been reported who accumulated amyloid burdens comparable to or exceeding those of their symptomatic relatives but remained free of dementia for decades beyond the expected age of onset. One, homozygous for the rare APOE3 Christchurch variant, showed high amyloid-PET signal but limited tau spread and cortical atrophy, and did not develop dementia until her seventies, roughly three decades later than expected. A second, carrying a rare RELN variant, showed a similarly protected trajectory. In both cases, protection appears to act downstream of amyloid, limiting tau propagation and the associated neuroinflammatory and neurodegenerative cascade.

This principle extends well beyond rare genetic forms of the disease. Population-based cohorts and biomarker studies consistently show that a substantial proportion of cognitively unimpaired older adults fulfill biological criteria for Alzheimer’s disease while remaining clinically normal for prolonged periods. A meta-analysis of biomarker-defined cohorts found that amyloid positivity increased the risk of clinical progression, but that this risk rose markedly when concomitant tau pathology was present. Amyloid positivity, in other words, identifies a state of increased biological susceptibility rather than an inevitable clinical destiny, much as plaque presence flags vascular risk without dictating a heart attack.

Therapeutic trials reinforce the same lesson. Anti-amyloid monoclonal antibodies such as lecanemab and donanemab have unequivocally demonstrated that cerebral amyloid can be substantially reduced in living brains. Across pivotal Phase III trials, treatment slowed cognitive decline but did not arrest disease progression, and clinical benefits have been consistently modest relative to the magnitude of amyloid removal. The authors caution that these results should not be read as a failure of the amyloid hypothesis. Rather, they suggest that amyloid removal alone may be insufficient once downstream cascades, including tau spread, synaptic dysfunction, neuroinflammation, and neuronal loss, have become established. Modifying the pathological substrate does not necessarily abolish the network of mechanisms ultimately responsible for cognitive decline, just as clearing one plaque does not eliminate the systemic biology of cardiovascular disease.

Community-based neuropathological studies add a further, often underappreciated, dimension. Unlike clinic-based autopsy series, cohorts such as the Religious Orders Study, the Rush Memory and Aging Project, and the Medical Research Council Cognitive Function and Ageing Study examine brains irrespective of ante-mortem diagnosis, offering a more representative picture of brain aging. These studies consistently show that pure Alzheimer’s disease is the exception rather than the rule in older adults. Most individuals with dementia harbor multiple co-existing pathologies, including cerebrovascular disease, Lewy body pathology, limbic-predominant age-related TDP-43 encephalopathy, hippocampal sclerosis, and argyrophilic grain disease. Crucially, co-pathologies are not incidental: each additional pathology lowers the threshold of Alzheimer’s neuropathologic change required for clinically overt dementia, while individuals with substantial amyloid but limited co-existing disease may remain cognitively preserved.

The authors also elevate the concept of biological resilience, distinguishing it from brain reserve, the structural capacity to tolerate pathology, and cognitive reserve, the ability to sustain performance through more efficient neural networks shaped by education and cognitive engagement. Biological resilience refers instead to intrinsic molecular, cellular, vascular, and immunological mechanisms that limit the pathological consequences of Alzheimer’s disease despite the presence of its defining lesions. Evidence is accumulating rapidly: the protected Colombian carriers demonstrate that extensive amyloid can coexist with preserved cognition when tau spread is restrained, and genetic modifiers such as APOE, RELN, and microglial genes like TREM2 show that resilience is partly biologically encoded. Resilience likely emerges from the interaction of many systems, including tau propagation control, synaptic integrity, innate immune regulation, blood-brain barrier maintenance, cerebrovascular health, mitochondrial function, proteostasis, and metabolic homeostasis.

This framework also reframes the meaning of modifiable risk factors. The 2024 Lancet Commission on dementia prevention identified 14 potentially modifiable factors, including lower educational attainment, hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, smoking, hypertension, obesity, excessive alcohol consumption, social isolation, air pollution, and untreated vision loss. Viewed through the new lens, these are not merely contributors to dementia risk but determinants of the brain’s resilience or vulnerability to Alzheimer’s pathology. Hypertension, diabetes, obesity, dyslipidemia, smoking, and air pollution promote endothelial dysfunction, blood-brain barrier impairment, cerebrovascular injury, oxidative stress, and chronic inflammation, lowering the threshold at which amyloid translates into neuronal dysfunction. Conversely, education, cognitive stimulation, physical activity, social engagement, and preserved sensory function help the brain tolerate pathological burden. The parallel with cardiology is direct: plaque identifies the underlying disease, but systemic risk factors determine whether it ever produces an event.

The practical implication is a shift from biological diagnosis to biological risk stratification. Current NIA-AA criteria answer with remarkable precision whether an individual has biological Alzheimer’s disease, but they are not designed to answer who will progress, when, or through which pathways. The authors propose that once biological Alzheimer’s disease is established, clinical decision-making should integrate amyloid and tau biomarkers with measures of neurodegeneration, cerebrovascular injury, co-existing proteinopathies, neuroinflammation, genetic susceptibility, metabolic health, and cognitive reserve to estimate the probability and pace of clinical conversion. The next frontier, they conclude, is not to move beyond amyloid but to move beyond an amyloid-centric interpretation of the disease. If amyloid defines the biological identity of Alzheimer’s disease, resilience may ultimately define its clinical destiny, and integrating pathological burden with the determinants of resilience and vulnerability could provide the foundation for truly personalized prediction, prevention, and treatment.

Subject of Research: A conceptual framework comparing Alzheimer's disease progression beyond amyloid pathology with atherosclerosis risk biology

Article Title: Alzheimer's Disease Beyond Amyloid: Lessons From Atherosclerosis

Article References: Ciaccio, M., & Agnello, L. (2026). Alzheimer's Disease Beyond Amyloid: Lessons From Atherosclerosis. Annals of Clinical and Translational Neurology, Article acn3.70533. https://doi.org/10.1002/acn3.70533

Image Credits: AI Generated

DOI: 10.1002/acn3.70533

Keywords: Alzheimer's disease, amyloid, tau, atherosclerosis, biological resilience, biomarkers, neuroinflammation, cerebrovascular disease, Lancet Commission, anti-amyloid therapies, mixed neuropathology, precision medicine